A Viral Path to Parkinson’s
Texas A&M University researchers have developed a new experimental model for Parkinson’s disease that uses the Theiler’s murine encephalomyelitis virus (TMEV) to trigger neurodegeneration in mice. The findings, published in the journal Brain, Behavior, and Immunity-Health, offer a non-toxic method to track how viral infections drive the loss of dopamine-producing neurons and the onset of motor impairment.
Moving Beyond Chemical Stressors
Standard Parkinson’s research has long relied on genetic modifications or neurotoxins to force symptoms in laboratory animals. While these methods are historical staples, they often fail to capture the multifactorial nature of the disease in humans.
The TMEV model provides a more naturalistic alternative. When the virus infects mice, it specifically targets dopamine-producing neurons. Within one month, researchers observed a significant destruction of these cells in affected brain regions. This process mirrors the progressive neuronal loss seen in human patients, allowing scientists to study the disease’s origins without relying on artificial chemical stressors.
The Role of Individual Susceptibility
The connection between viruses and neurodegeneration has long been a subject of scientific inquiry. Candice Brinkmeyer-Langford, a researcher at Texas A&M, noted that toxic exposure models do not account for the reality that many people exposed to similar environmental chemicals never develop the disease.
Using a virus allows researchers to better simulate biological complexity. Brinkmeyer-Langford emphasized that individual susceptibility—influenced by genetics and prior exposure to pathogens like the Epstein-Barr virus or SARS-CoV-2—plays a critical role in how an infection might eventually lead to neurodegeneration. This model clarifies those interactions in ways previous methods could not.
Tracking Progressive Motor Decline
To validate the model, the team monitored the physical health of infected mice. The results showed a progressive deterioration in motor function that closely mirrored the clinical symptoms of human Parkinson’s. Key observations included:
- Gait and Balance: The mice exhibited significant, measurable alterations in their walking patterns and stability.
- Coordination: There was a marked decline in movement speed and overall physical coordination.
- Progression: The symptoms worsened over time, suggesting that the viral infection sets off a cascade of damage rather than a singular, static event.
Bridging the Clinical Gap
Parkinson’s disease currently affects more than 10 million people worldwide. As the global population ages, that number is expected to rise.
The Texas A&M team intends to use the TMEV model to bridge the gap between animal testing and human clinical outcomes. By comparing this viral model to traditional systems, scientists hope to identify early-stage biomarkers that could signal the onset of Parkinson’s before severe symptoms appear. Furthermore, the study creates a foundation for investigating how the immune system’s response to viral pathogens might be a primary driver of the disease, potentially opening doors for therapeutic interventions focused on immune modulation.